EP2152273A2 - Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs - Google Patents

Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs

Info

Publication number
EP2152273A2
EP2152273A2 EP08758070A EP08758070A EP2152273A2 EP 2152273 A2 EP2152273 A2 EP 2152273A2 EP 08758070 A EP08758070 A EP 08758070A EP 08758070 A EP08758070 A EP 08758070A EP 2152273 A2 EP2152273 A2 EP 2152273A2
Authority
EP
European Patent Office
Prior art keywords
hexyl
isohexyl
pentyl
butyl
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08758070A
Other languages
German (de)
English (en)
Inventor
Monika SCHÄFER-KORTING
Hans-Dieter Höltje
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Freie Universitaet Berlin
Heinrich Heine Universitaet Duesseldof
Original Assignee
Freie Universitaet Berlin
Heinrich Heine Universitaet Duesseldof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07090098A external-priority patent/EP1990054A1/fr
Application filed by Freie Universitaet Berlin, Heinrich Heine Universitaet Duesseldof filed Critical Freie Universitaet Berlin
Priority to EP08758070A priority Critical patent/EP2152273A2/fr
Publication of EP2152273A2 publication Critical patent/EP2152273A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the invention relates to polymerase inhibitors, in particular polymerase alpha inhibitors and their use in cell growth disorders, in particular tumor diseases, preferably actinic keratoses, basaliomas and / or spinocellular carcinomas.
  • Tumor diseases are used synonymously with cancer. This is understood to mean in particular malignant tumors. In the narrower sense, however, malignant haemoblastoses are also defined as cancer in medical circles (eg leukemia as blood cancer). Cancer is used as a collective term for a variety of related diseases in which body cells can grow uncontrollably, divide and displace healthy tissue or infiltrate or destroy it.
  • malignant skin tumors also referred to as malignant tumors or skin cancer or malignant melanoma
  • malignant tumors or skin cancer or malignant melanoma are among the most common tumor diseases in humans. Often these arise on skin areas that are exposed to solar radiation, such. B. on the head, upper body, the calves of cyclists. In general, people are often affected who spend a lot of time outdoors, such as As farmers, sailors or fishermen. Since specific layers of the population equate brown skin with recovery and dynamism, there has been a significant increase in cancer in recent years. Especially in countries with high solar radiation such. B. Australia has come to an alarming accumulation of skin cancers. But in Germany, too, about 8,000 people are suffering from a particularly malignant form of skin cancer, malignant melanoma (dark skin cancer).
  • UV light in the development of pale skin cancer (actinic keratons, spinocellular carcinoma and basalioma).
  • the drug of choice for basal cell carcinoma and spinalioma is the surgical removal of the tumor.
  • Malignant melanoma is among the tumors that metastasize the earliest.
  • the secondary tumors must also Rurigisch be removed.
  • immunotherapy is often performed.
  • the body's defenses are to be started. Chemotherapy with cytostatics is now used only to a very limited extent as the only therapy. This is due to the fact that with such agents, the tumors mentioned can not be treated locally limited.
  • the object of the invention was therefore to provide, in particular, specific selected nucleosides which have a surprisingly good effect on selected tumors.
  • an antitumour agent in particular for the treatment of dermal tumors, selected from the group comprising compounds according to the general formulas (1) to (16):
  • R 1 H or mono- or di- or
  • Triphosphate R 2 butyl or pentyl or hexyl or
  • R.2 butyl or pentyl or hexyl or isohexyl derivative (3)
  • Ri H or mono- or
  • Diphosphate R 2 butyl or pentyl or
  • Ri H or mono- or di- or triphosphate
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 O or NOH
  • R 4 OH or SH
  • R 1 O or NOH
  • Ri H or mono- or di- or triphosphate
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 OH or H
  • R 4 OH or SH
  • Ri H or mono- or diphosphate
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 OH or H
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 OH or SH.
  • the teaching according to the invention combines a uniform group of inventions which are interconnected by a single general inventive idea.
  • the claimed compounds can be considered as alternatives with common properties or effects. All alternatives belong to a known class of chemical compounds in the field of the invention.
  • the teaching according to the invention is also a selection invention in which selected nucleosides with surprising properties are selected for the action of tumors, in particular skin tumors or skin cell growth disorders.
  • an agent in particular for the treatment of cell modifications preferably in a skin area, in particular selected from the group comprising actinic keratosis, malignant melanomas, spinocellular carcinomas and / or basaliomas, which have an improved antiproliferative activity towards diclophenac and / or 5-Fu, wherein they are selected from the group comprising compounds according to the general formulas 1 to 4:
  • Ri H or mono- or di- or
  • Triphosphate R 2 butyl or pentyl or hexyl
  • Triphosphate R 2 butyl or pentyl or
  • R 1 H or mono- or
  • R * butyl or pentyl or
  • R, butyl or pentyl or
  • the agents according to the invention modulate, in particular inhibit, a polymerase, in particular polymerase alpha. This technical teaching helps one of ordinary skill in the art to treat new patient populations and new diseases that were untreatable with the prior art agents.
  • a skin area within the meaning of the invention is any area that is associated with the epidermis, the Dennis, the subcutis or skin appendages, the groin skin or the pelvic skin, these forms wholly or partially, or is present as such, or is associated with them.
  • the skin may be, for. These can be, for example, breast, colon and rectum or bladder tissues.
  • the skin is understood in preferred embodiments in particular but not exclusively as an external organ of the human or animal organism, which serves the delimitation of the inside and outside.
  • skin components in a preferred embodiment include components of the epidermis, dermis or subcutis.
  • the epidermis (epidermis) according to the invention consists of the following layers: Hom harsh (stratum corneum), luminescent layer (stratum lucidum), Kömer- layer (stratum granulosum), prickle cell layer (stratum spinosum) and / or basal layer (stratum basale). Any modification of cells in this area is a cell modification in a dermal area within the meaning of the invention.
  • the dermis (dermis, corium), which may also be a component of the skin areas according to the invention, consists predominantly of connective tissue fibers and serves for nutrition and anchoring of the epidermis.
  • the capillarized blood vessel system in the border zone to the epidermis belongs to the skin area according to the invention as well as the sebaceous and sweat glands.
  • the Dennis according to the invention can be divided into a stratum papillar and a stratum reticulare.
  • a skin area within the meaning of the invention any area, d. H. any place in or on the subcutis or tissue inside the body or any organ or organ component.
  • a tissue barrier that separates an organ from the surrounding structures may be a skin according to the invention.
  • the term of the skin area according to the invention also includes skin appendages, such as hair, sebaceous glands, Haarbalgmuskeln, nails, Homer and sweat glands, in particular the eccrinen and the apocrine sweat glands, but also the mammary glands.
  • skin appendages such as hair, sebaceous glands, Haarbalgmuskeln, nails, Homer and sweat glands, in particular the eccrinen and the apocrine sweat glands, but also the mammary glands.
  • Any cell modification in particular a non-normal cell growth, can be treated with the agents according to the invention, preferably without being restricted to the external skin areas.
  • the skin areas within the meaning of the invention may also relate to the groin skin, as they occur on the fingers or on the sole of the foot, or else the field skin and the skin appendages associated therewith.
  • Swelling or puffiness may form wholly or in part on all types of skin. That is, there may be an increase in tissue volume of any cause. Of course, it is also possible that there is a decrease in the tissue volume.
  • These changes in the tissue volume are understood in one embodiment of the invention as cell modifications within the meaning of the invention.
  • changes in the activity of the cells without there being an increase or decrease in the tissue volume can also be cell modifications within the meaning of the invention, for example if certain modified cells also belong to another cell tissue which may or may not belong to a skin area do not infiltrate or invade.
  • These processes are also understood as cell modifications in the sense of the invention.
  • an inflammation that affects a skin area or adjacent to this is a cell modification in the context of the invention.
  • Preferred cell modifications in a dermal area are actinic keratosis, malignant melanomas, spinocellular carcinomas or basaliomas.
  • the actinic keratosis in the context of the invention is a change in the skin, in particular the keratinized epidermis, caused in particular by photodamage. Actinic keratosis can degenerate malignantly and lead to skin cancer (facultative precancerosis). Actinic keratosis affects humans in all years of life, but in a preferred embodiment of the invention especially those in the second half of life. Actinic keratosis occurs in a zugtenticiansfom ⁇ the invention in particular on the face, on the back of the hand, the forehead, in the top of the head / Glafze, on the nose and the ear.
  • actinic keratosis is of course not limited to humans, but it affects all living things, especially mammals, particularly preferably domestic dogs and domestic cats. It is of course possible that actinic keratosis, as a cell modification in a skin area, may be associated with other skin lesions, such as precancerous lesions, or not associated with it, at the same time or with a time lag in an organism (eg, Bowen's disease).
  • the basalioma in the context of the invention is a basal cell cancer or precursors of this cancer, which may also be referred to as epithelioma basocellulare.
  • this cell modification can start from the basal epidermis cell layers. It can also damage the surrounding non-skin tissue and infiltrate the bone cells.
  • Each treatment of such a cell modification is understood as a treatment of a cell modification of a skin area within the meaning of the invention, especially since the cell modification starts from a skin area, namely the epidermis cell layers.
  • a spinocellular carcinoma according to the invention is a cell modification in a skin area, which is triggered in particular by UV light and therefore occurs in particular at body sites, which - like the basalioma - are exposed to light, such as the face.
  • Precancerous lesions such as actinic keratosis and Bowen's disease may, in preferred embodiments of the invention, be regarded as spinal disorders.
  • the metastases which are formed by the spinal or, for example, the basalioma are also understood in the sense of the invention as a cell modification in a skin area.
  • a malignant melanoma according to the invention is any particular malignant (malignant) degeneration of pigment cells (melanocytes).
  • Malignant melanoma has a strong tendency to spread early metastases through the lymphatic and bloodstream systems.
  • the invention as a cell modification in a dermal area also includes the treatment of metastases emanating from a malignant melanoma.
  • the agent according to the invention is suitable, in particular, for influencing, in particular inhibiting, the polymerase of the cells that have been modified by increasing their growth or changing their biochemical activity.
  • the agents according to the invention can therefore be used in particular in tumors in connection with influencing, reduplication or repair of DNA or RNA.
  • the effect on tumors is preferably not limited to skin tumors.
  • the agents according to the invention are used in particular in the local therapy of tumors that occur in a skin area, wherein these tumors may be primary or secondary tumors in the skin area.
  • a preferred target of the agents according to the invention are the polymerases which are present in the tumor tissue-that is to say in particular in the cells.
  • the structures according to the invention can be used particularly effectively for the treatment, in particular, of skin tumors.
  • the agents according to the invention have a high affinity for the polymerase alpha, which no longer binds to a primase such that the replication of the main and subsequent strings can not take place.
  • the agents according to the invention can be used against all polymerases, in particular eukaryotic polymerases, preferably of the classes A, B, X and Y.
  • the effect of the agents on the polymerase alpha in connection with the treatment of the cell modifications mentioned is surprising.
  • the agents according to the invention can therefore, in preferred embodiments of the invention, also be used as DNA polymerase inhibitors. Be designated inhibitor.
  • the structures according to the invention can also be used as a lead structure for the development of other polymerase inhibitors, in particular polymerase-alpha inhibitors.
  • the invention is of course not limited only to the means according to the invention, but also relates to functionally analogous molecules which, compared to the molecules preferably according to the formulas 1 to 4 or preferably according to the formulas 1 to 7, a similar behavior in the solution of the problem according to the invention demonstrate.
  • Functional analogs within the meaning of the invention are to be construed as equivalents that can be generated differently but perform essentially the same function in substantially the same way and produce substantially the same result as preferred compounds according to the general formulas 1 to 4 or 5, 6 or 7.
  • the functionally analogous molecules according to the invention would be those which the person skilled in the art would find to have the same effect, the expert having to consider this, in particular based on the meaning of the doctrine under protection, the skilled person being able to use the function analogues or variants as a solution in Consideration which is equivalent to the solution according to the invention claimed molecules preferably according to the general formulas 1 to 4.
  • function analog or “variants” and “substantially the same function”, “in substantially the same way” and “substantially the same result” are not relative terms, as the terms in question are of generally accepted meaning in the relevant field of biology Since the terms function analogues and variants according to the invention are understood as equivalents and these terms have been defined several times by the case law (inter alia in the draft international patent harmonization contract), the terms are also sufficiently clear Meaning that they should not be replaced by more precise information.
  • substantially is authorized as defined in the International Patent Law Harmonization Treaty because it serves as a "soft-focus" for too narrow or narrowly defined claims the
  • the term “substantially” is intended to avoid that a molecule which is a variant of the molecules claimed according to the invention and produces substantially the same function in substantially the same way with substantially the same result is no longer covered by the claims if, for example does not exactly produce the identical result, or if slightly modified conditions for optimal use are required for the use of such functional analogs or variants.
  • the term "in essentially the same way” therefore means in the context of the invention that the functional analogues or variants can be used in particular for the treatment of actinic keratoses, malignant melanoma, spinocellular carcinomas and / or basaliomas on areas of skin.
  • the agent according to the invention has the following structure:
  • the agent according to the invention has the following structure: (6)
  • the agent according to the invention has the following structure:
  • the invention also relates to agents which are functionally analogous to the compounds according to the general formulas 1 to 7 and which are selected from the group encompassing (8th)
  • R 1 H or mono- or di- or triphosphate
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 O or NOH
  • R 1 H or mono- or di- or triphosphate
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 H or OH
  • R 4 OH or SH
  • Ri H or mono- or diphosphate
  • R 2 BuIyI or pentyl or hexyl or isohexyl derivative
  • R 1 H or mono- or diphosphate
  • R 2 butyl or pentyl or hexyl or isohexyl derivative
  • R 3 OH or SH.
  • the invention also relates to a compound of general formula 10
  • R 1 O or NOH 3'-deoxy-3'-oxothymidine or
  • HM-1 is claimed in a first medical indication and HM-1 oxime derivative in a use for the treatment of tumors (second medical indication). Accordingly, HM-1 and HM-1 oxime derivatives are both claimed as anti-tumor agents, especially for cell growth disorders of the inner and outer skin. It was completely surprising that the compound according to the general formula 10 can be used for the prophylaxis or for the therapy or after-treatment of tumor diseases, in particular of skin tumors.
  • the compounds according to the general formulas 1 to 16 represent a unit, since this solves the problem underlying the invention.
  • the connections are interconnected in such a way that they realize a single general inventive idea.
  • compositions of the invention may be applied so as to prevent or inhibit the growth, metastasis, invasion, infiltration and / or angiogenesis of the tumor.
  • the effect of the compounds of the invention on tumors with regard to their prophylactic or therapeutic potential is shown for.
  • the dose administered will depend on the age, the health and weight of the recipient, the degree of the disease, the type of necessary co-treatment, the frequency of treatment and the type of effects desired, and Side effects.
  • the particular dose or dose range for the administration of the pharmaceutical agent according to the invention is large enough to achieve the desired prophylactic or therapeutic antitumoral effect.
  • the dose should not be chosen so that unwanted side effects dominate.
  • the dose will vary with the age, constitution, sex of the patient and, of course, the severity of the disease.
  • the individual dose can be adjusted both in relation to the primary disease and in terms of the occurrence of additional complications.
  • the exact dose can be determined by a person skilled in the art by known means and methods, for example by determining the size of the tumor, the leukocyte count or the like as a function of the dose or depending on the treatment scheme or the pharmaceutical carriers and the like.
  • the dose can be selected individually depending on the patient.
  • a dose of the pharmaceutical agent still tolerated by the patient can be one whose range in the plasma or in individual organs is locally in the range from 0.1 to 100,000 ⁇ M, preferably between 1 and 1,000 ⁇ M.
  • the dose may also be calculated in relation to the body weight of the patient.
  • a typical dose of the pharmaceutical agent would be in the range of more than 0.1 mg per kg body weight, preferably between 0.1 and 5000 mg / kg.
  • Such a gel may contain, for example, 1 to 1000 mg of the compounds of the invention or the pharmaceutical agent per ml of gel composition, preferably between 5 to 500 mg / ml and more preferably between 10 and 100 mg / ml.
  • the therapeutic agent is administered as a solid, gel or liquid composition.
  • the compounds can furthermore be used in a total amount of 0.05 to 500 mg / kg body weight per 24 hours, preferably from 1 to 10 mg / kg Body weight.
  • This is advantageously a therapeutic amount used to prevent or ameliorate the symptoms of a disorder or responsive, pathologically physiological condition.
  • the amount administered is sufficient to prevent or inhibit the growth, metastasis, invasion, infiltration and / or angiogenesis of the tumor.
  • the effect of the compound of the invention on the tumors with regard to their prophylactic or therapeutic potential is shown, for example, as inhibition of growth or otherwise.
  • the therapeutic effect may also be, for example, that certain antitumoral drugs work better as a desired side effect by the application of the compounds according to the invention or, by reducing the dose, the number of side effects of these medications. is reduced.
  • the therapeutic effect also includes a direct action on the tumor.
  • this means that the effect of the compounds according to the invention is not limited to an elimination of the tumors, but encompasses the entire spectrum of advantageous effects in the prophylaxis and therapy.
  • the dose will depend on the age, the health and weight of the recipient, the degree of the disease, the nature of a necessary concomitant treatment, the frequency of treatment and the nature of the effects desired and the side effects.
  • the daily dose of 0.05 to 500 mg / kg body weight can be used once or several times to obtain the desired results. Dosage levels per day are useful in the prevention and treatment of a tumor disease.
  • the active ingredient amounts combined with the carrier materials to produce a single dosage form may, of course, vary depending on the subject to be treated and the particular mode of administration. It is preferred to distribute the target dose to 2 to 5 applications, with 1 to 2 agents (patches, tablets etc.) are administered with an active ingredient content of 0.05 to 5 mg / kg body weight in each application. Of course it is possible to choose the active ingredient content also higher, for example up to a concentration above 500 mg / kg.
  • the invention accordingly relates to the claimed agents according to general formulas 1 to 9 and 11 to 16, preferably for use as medicaments.
  • the agents are preferably used as pharmaceutical agents which comprise the agent according to the invention and optionally a pharmaceutically acceptable carrier.
  • the compounds according to the general formula 1 to 16 are connected by the functional relationship with each other to a uniform inventive idea that they have a common effect. This joint effect consists in their surprisingly good usability in tumor therapy.
  • the invention accordingly relates in a particular aspect to the surprising teaching that the compounds according to the general formulas (1) to (16) can be used for the treatment of tumors of the skin in a particularly specific manner and with a particularly good efficiency. It was completely surprising that the compounds of the invention according to the general formulas (1) to (16) can be used particularly well in tumor therapy. Although similar compounds have been described in the prior art, they do not have these surprising properties.
  • the inventive activity of the compounds of general formulas (1) to (16) for their new use can not be denied because they are similar to known chemical compounds, since this would imply that the average expert would have expected that the new use of partially new compounds as a means of solving the underlying technical problem as well or similarly well would be like the known ones.
  • the existing differences to known chemical compounds have a significant influence on the properties of the claimed claims according to the invention and thus have great importance for the solution of the technical problem.
  • the compounds according to the general formulas (1) to (16) in contrast to the known ones, have little or no effect on normal cells, but are very toxic when they are brought into contact with cancer cells.
  • the structures according to the invention also have increased lipophilicity over the known compounds.
  • the pharmaceutical carrier is selected from the group comprising fillers, diluents, binders, humectants, dissolution inhibitors, disintegrants, absorption accelerators, wetting agents, absorbents, lubricants and / or carrier lipids, in particular solid lipid nanoparticles, nano-structured lipid carriers, Liposomes but also polymer particles, in particular dentrimers.
  • a pharmaceutical agent in the context of the invention is any agent in the field of medicine, which can be used in the prophylaxis, diagnosis, therapy, follow-up or after-treatment of patients who have come in contact with tumor cells or carcinogens in particular so that at least temporarily pathogenic modification of the overall state or condition of individual parts of the organ could establish ganism.
  • the pharmaceutical agent in the sense of the invention may be a vaccine, an immunotherapeutic or an immunoprophylactic agent.
  • the pharmaceutical agent according to the invention may comprise the compound of the invention or the compound of the invention and / or an acceptable salt or components thereof.
  • the invention also relates to a kit comprising the pharmaceutical agent according to the invention, together with an application system and information for combining the contents of the kit.
  • the information for combining the contents of the kit relates to the use of the kit for the prophylaxis and / or therapy of diseases, in particular tumoral diseases.
  • the information can also relate, for example, to a therapeutic regimen, that is to a specific injection or application regimen the dose to be administered or otherwise.
  • the invention relates to the use of the agents according to the invention, the pharmaceutical compositions according to the invention and the kit according to the invention for modifying a polymerase in vitro or in vivo.
  • the polymerase is a DNA polymerase alpha.
  • the modification of the polymerase is the modification of cell growth and / or cell growth disorder.
  • the cell growth disorder is a cell proliferation.
  • tumor in the invention, is meant to encompass any disease circumscribed by the term cancer.
  • any tissue proliferation or mass in a human or animal body can also be understood as a tumor in the sense of the invention, especially if this mass or tissue proliferation takes place on a skin surreal.
  • the mass and tissue proliferation includes both swelling, inflammation and neoplasm of body tissue due to dysregulation of cell growth.
  • benign tumors such as moles or fatty tumors in the context of the invention are defined as a tumor.
  • the malignant skin tumors may be, for example, a basalioma (basal cell carcinoma), a spinal cell (spinal cell carcinoma) or, for example, a malignant melanoma (black skin cancer).
  • the cell proliferation is selected from the group comprising skin cancer originating in the epithelium, preferably a basalioma or Spinalioma, pigmentary cell skin cancer, immune cell skin cancer, fibrosarcoma, sweat gland cancer, sebaceous gland cancer, angiosarcoma, myosarcoma and / or Merkel cell carcinoma.
  • the basalioma is nodular, solid basalioma, a superficial basalioma, a pigmented basalioma, a sclerosingly-growing basalioma, an exulsively-growing basalioma, and / or a destructively-growing basalioma.
  • the cell growth disorder is a keratosis.
  • the keratosis is selected from the group comprising seborrheic keratosis, actinic keratosis, age spots, pigment spots and / or lentigo solaris.
  • the tumor disease is a carcinoma, a sarcoma, a neuroendocrine tumor, a hemooncological tumor, a dysontogenetic tumor and / or a mixed tumor.
  • the disease is a cancer that is prevented, prevented, or prevented from recurring, selected from the group of cancers or tumors of the ear, nose and throat, lung, mediastinum, gastrointestinal tract, genitourinary system gynecological system, breast, endocrine system, skin, bone and soft tissue sarcomas, mesotheliomas, melanomas, central nervous system neoplasms, childhood cancers or tumors, lymphomas, leukemia, paraneoplastic syndromes, metastases without known primary tumor (CUP syndrome), peritoneal carcinoma, immune suppression-related malignancies and / or tumor metastases.
  • CUP syndrome primary tumor
  • the tumors may be the following cancers: adenocarcinoma of the breast, prostate and colon; all forms of lung cancer originating from the bronchi, bone marrow cancer, melanoma, hepatoma, neuroblastoma; the papilloma; Apudom, Choristom, Branchioma; the malignant carcinoid syndrome; carcinoid heart disease; carcinoma (for example, Walker's carcinoma, basal cell carcinoma, basosquamous carcinoma, Brown-Pearce's carcinoma, ductal carcinoma, Ehrlich's tumor, in situ
  • carcinoma for example, Walker's carcinoma, basal cell carcinoma, basosquamous carcinoma, Brown-Pearce's carcinoma, ductal carcinoma, Ehrlich's tumor, in situ
  • Carcinoma cancer 2 carcinoma, Merkel cell carcinoma, mucous carcinoma, non-small cell bronchial carcinoma, oat cell carcinoma, papillary carcinoma, cirrhotic carcinoma, bronchiolo-alveolar carcinoma, bronchial carcinoma, squamous cell carcinoma and transitional cell carcinoma); histiocytic dysfunction; Leukemia (for example, B-cell leukemia, mixed cell leukemia, null cell leukemia, T-cell leukemia, chronic T-cell leukemia, HTLV-II associated leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, mast cell leukemia and myeloid leukemia); malignant histiocytosis, Hodgkin's disease, non-Hodgkin's lymphoma, solitary plasma cell tumor; Reticuloendotheliosis, chondroblastoma; Chondroma, chondrosarcoma; fibroma; fibrosarcoma; Giant cell
  • the cancer or tumor being treated is prophylactically prevented or prevented from recurring, selected from the group of cancers or tumors selected from the group: tumors of the ear, nose and throat region comprising tumors the internal nose, paranasal sinuses, nasopharynx, lips, oral cavity, oropharynx, larynx, hypopharynx, ear, salivary and paragangliomas, tumors of the lung comprising non-small cell lung carcinomas, small cell lung carcinomas, tumors of the mediasti - nums, tumors of the gastrointestinal tract comprising tumors of the esophagus, stomach, pancreas, liver, gallbladder and biliary tract, small intestine, colon and rectal cancers and anal carcinomas, urogenital tumors including tumors of the kidneys, ureters, bladder, prostate , the urethra, the penis and the testicles, gynecological tumors including tumors of the group: tumors of the
  • the cancer or tumor being treated is prophylactically prevented or prevented from recurring selected from the group consisting of cancers or tumors of breast cancers, gastrointestinal tumors including colon carcinomas, gastric carcinomas, colon and small intestinal cancers, pancreatic carcinomas , Ovarian Cancer, Liver Cancer, Lung Cancer, Renal Cell Carcinoma and Multiple Myeloma.
  • the active compounds according to the invention for the topical and systemic treatment of the breast, colon and rectum and the bladder.
  • agents according to the invention can be used for the treatment of keloids as well as plaque psoriasis.
  • the agent is in the form of a solution, emulsion, suspension, ointment, a balm, oil, gel, foam, eye balm, eye gel, suppository, sprays, patches, sticks or sticks, in liquid form, in the form of artificial tears, as a thermoreversible gel (to be used liquid), in the form of a tampon containing active ingredient and / or in the form of a cream.
  • a solution, emulsion, suspension, ointment, a balm, oil, gel, foam, eye balm, eye gel, suppository, sprays, patches, sticks or sticks in liquid form, in the form of artificial tears, as a thermoreversible gel (to be used liquid), in the form of a tampon containing active ingredient and / or in the form of a cream.
  • liquid forms which may preferably be anhydrous or hydrous, wherein the hydrous according to the invention can be distinguished in single-phase systems and in multi-phase systems.
  • semi-solid forms that are anhydrous or hydrous can be used, which in turn is a division into single-phase systems and multi-phase systems in the water-containing semi-solid forms possible.
  • solid forms which are lipophilic or hydrophilic can preferably be used. Examples of such forms are in addition to the mentioned z. Greases, foams, powders, pens, Gel creams, hydrodispersion gels, low viscosity emulsions, lotions, ointments, sprays and creams.
  • aqueous systems single-phase systems such as solutions and microemulsions are preferred, in the multiphase systems, multiple emulsions, VWO emulsions or O / V emulsions are preferred.
  • solid / liquid systems preferred forms are the suspensions or the liquid / solid / liquid systems such as suspension / emulsion systems.
  • O ⁇ / emulsions preferred galenical conducting substances are O / W emulsifiers, W / O emulsifiers, liquid hydrophilic constituents and liquid lipophilic constituents.
  • preferred galenic lead substances are W / O emulsifiers, O / W emulsifiers, liquid and semi-solid lipophilic constituents, gelling agents, liquid hydrophilic constituents and / or salts.
  • anhydrous systems such as hydrous systems are preferred for different applications.
  • Anhydrous systems may consist of apolar systems or of polar systems without emulsifiers such as lipogels, oleogels or polyethylene glycol gels or of apolar systems with emulsifiers based on ONM absorption or W / O absorption bases.
  • the aqueous systems may preferably consist of single-phase systems such as hydrogels or microemulsion gels or multiphase systems such as O / W creams, W / O creams or amphiphilic systems.
  • the preferred semi-solid preparations are spreadable preparations in the temperature range between room temperature and skin temperature for use on the skin or on mucous membranes, which exert a local action, transport active substances or exert a softening or protective effect on the skin.
  • Preferred preparations are ointments in the strict sense, creams, gels and / or pastes.
  • oleogels can also be used as semi-solid, transparent single-phase systems.
  • the person skilled in the art is known, for example, from US Pat. No. 6,187,323 or Aiache et al.
  • bi-GeI various anhydrous compounds for the formulation of semi-solid systems known, such as the compound of an oleogel and a hydrogel, which according to the invention can be referred to as Bi-GeI.
  • hydrodispersion gels or various lipids can be used to provide carrier substances according to the invention.
  • organosilicon compounds as well as carbon-organic compounds can be used to provide lipid phases in disperse systems, whereby carbon-organic compounds can be used. can be provided, for example, by means of non-hydrolysable lipids or hydrolyzable lipids (glycerols), wax esters.
  • Advantages of such systems are the improved suppleness of the skin and the increase in its elasticity as well as its ability to influence release and penetration depending on the composition of the lipids.
  • the person skilled in the art knows which lipids to use, for example to increase or decrease the penetration within a time parameter.
  • Further preferred carrier substances are, for example, hydrodispersion gels or microcapsules, microspherules or pellets (Macrobeads).
  • the mentioned carriers serve to increase the stability and ensure a minimum application time on the skin.
  • the preferred semi-solid single-phase systems can be provided by the following galenic conductive substances: liquid hydrophilic ingredients, especially water and (poly) alcohols, hydrophilic gelling agents, salt formers and W / O emulsifiers, O / V emulsifiers, liquid, semi-solid and solid solvents. Pophile ingredients as well as lipophilic gel or scaffolding. The person skilled in the art knows how to combine these substances in order to achieve a specific effect.
  • Preferred products according to the invention are, for example, lipophilic or hydrophilic solutions, lipophilic or hydrophilic emulsions, lipophilic or hydrophilic suspensions, special liquid preparations, hydrophobic or hydrophilic ointments, water-emulsifying ointments, lipophilic, hydrophilic or amphiphilic creams, hydrogels, hydrophobic or hydrophilic pastes and / or Powder.
  • Nanotransport systems with dendritic architecture can also be used with particular advantage. This is included in the disclosure of the present application according teaching.
  • Various transport systems are known from the prior art, for example liposomes, polymer micelles, polyconjugates or simple dendritic core-shell architectures.
  • Polymeric micelles are physical aggregates of ambiphilic macromolecules that spontaneously self-assemble in water. Usually, the inner block is non-polar or ionic, and the outer block, which protects the nucleus by steric stabilization, is polar. They are often used to solubilize non-polar drugs or drug combinations with limited solubility in water or for the transport of oligonucleotides.
  • Nanotransport systems with simple dendritic core-shell architecture also allow targeted drug delivery.
  • the covalent modification of dendritic macromolecules with a corresponding shell provides stable micellar structures suitable for the encapsulation of drugs.
  • Particularly advantageous nanotransport systems can be used, which consist of at least one dendritic core and at least two shells.
  • the shells Preferably, the shells have different polarities, thus achieving a polarity gradient around which both non-polar and polar agents or combinations of agents can be included.
  • the advantageous nanotransport systems therefore advantageously have a multishell unimolecular structure.
  • transdermal therapeutic system with increased drug flux is disclosed in DE 10 2006026578, which is also included in the disclosure of the application.
  • This transdermal therapeutic system which is likewise preferred, can be used, for example, as a transdermal patch which has an active substance-containing matrix of the agents according to the invention.
  • the matrix can be made, for example, of rubber or other synthetic polymers in which water-soluble or water-swellable inclusion bodies are embedded, which contain micronized or nanoscale active substance particles which comprise the agents according to the invention.
  • this transdermal therapeutic system allows for improved stability and improved uniformity in providing increased drug flux with little adjunct to other prior art agents.
  • galenic vehicles can be used, which themselves have an antitumoral effect and can reach the topical application, such as the composition according to DE 03251 884 (EP 1 348441), which also in the disclosure of the teaching according to the application is included.
  • nanostructured lipid carriers for the dermal applications of the invention. Due to the special matrix structure of the nanostructured lipid carrier (NLC), the loading capacity is increased and particle dispersions can be prepared. which have the consistency of a cream or paste.
  • the NLC solid lipid matrix can protect the pharmaceutical agents of the invention from premature degradation.
  • the NLC form a film which reduces the loss of water of the skin and can lead to increased skin moisture, whereby an increased penetration of the active compounds according to the invention is made possible.
  • microcapsules based on liposomes such as. B. Smarticles and cagicles can be used advantageously.
  • colloidal drug forms such as nanoparticles, nanocapsules and micelles. These are stable physiological mixed micelles that can be used to advantage in certain tumors. But also supportive agents or pharmacological carriers from the Komeotherapie can be used. This is a so-called outside-in therapy, for the primary effect of which penetration through the horny layer is advantageous.
  • the actual active substances according to the invention for example in connection with ceramides, proteins and their synthetic analogues or peptides, would be used.
  • such compounds in combination with liposomes and nanoparticles can be adapted to the individual requirements and the specific tumors.
  • the galenic prerequisites for coma therapy are known to those skilled in the art, so that they can be applied to the teaching according to the invention.
  • the pharmaceutical agent according to the invention as gel, powder, powder, tablet, sustained-release tablet, premix, emulsion, infusion formulation, drops, concentrate, granules, syrup, pellet, BoIi, capsule, aerosol, spray and / or inhalant are prepared and used
  • the ointment is selected from the group comprising Unguentum leniens (cooling ointment), Unguentum emulsificans (hydrophilic ointment), Unguentum emulsificans aquosum (hydrous hydrophilic ointment), Unguentum cetomacrogolis, Unguentum cetylicum cum aqua (Celylsalbe), Unguentum Alcoholum Lanae or Unguentum adeps lanae (wool wax alcohol ointment, Eucerin) Unguentum molle (soft ointment) and / or Unguentum Zinci (zinc ointment).
  • Unguentum leniens cooling ointment
  • Unguentum emulsificans hydrophilic ointment
  • Unguentum emulsificans aquosum hydrous hydrophilic ointment
  • Unguentum cetomacrogolis Unguentum
  • the pharmaceutical agent according to the invention is present in a concentration of from 0.1 to 99.5, preferably from 0.5 to 95.0, particularly preferably from 20.0 to 80.0% by weight in one Preparation before.
  • the compounds of the present invention are present in the pharmaceutical compositions listed above, for example, tablets, pills, granules, and others, preferably in a concentration of from 0.1% to 99.5% by weight of the total mixture.
  • the amount of active ingredient that is to say the amount of a compound of the invention combined with the carrier materials to produce a single dosage form, will vary depending on the subject to be treated and the particular mode of administration. After improving the condition of a patient, the proportion of active compound in the preparation be changed so that a maintenance dose is present. Thereafter, the dose or frequency of administration, or both as a function of the symptoms, may be reduced to a level at which the improved condition is maintained. When the symptoms have been alleviated to the desired level, treatment should cease.
  • the proportion of the compounds, that is their concentration, in the overall mixture of the pharmaceutical preparation as well as their composition or combination is variable and can be modified and adapted by one skilled in the art on the basis of his expertise.
  • the compounds according to the invention can be brought into contact with an organism, preferably a human or an animal, in various ways. Furthermore, it is known to the person skilled in the art that, in particular, the pharmaceutical agents can be administered in various dosages.
  • the application should be carried out in such a way that the tumorous disease is combated as effectively as possible or the onset of such a disease is prevented in a prophylactic administration.
  • concentration and the type of application can be determined by the skilled person through routine experimentation.
  • Preferred applications of the compounds according to the invention are, in addition to the dermal, the oral or other application in the form of powders, tablets, juice, drops, capsules or the like, the rectal administration in the form of suppositories, solutions and the like, parenterally in the form of injections, infusions and solutions , Inhalation of vapors, aerosols and dusts and plasters and locally in the form of ointments, patches, envelopes, rinses and the like.
  • the contacting of the compounds according to the invention preferably takes place prophylactically or therapeutically. In a prophylactic administration, the establishment of a tumor should be prevented.
  • the cancer cells already in the body are either to be killed or inhibited in their multiplication.
  • Further preferred forms of administration for this purpose are, for example, the subcutaneous, the sublingual, the intravenous, the intramuscular, the intraperitoneal and / or the topical.
  • the suitability of the chosen administration forms as well as the dose, the application scheme, the adjuvant choice and the like can be determined, for example, by taking serum aliquots from the patient or imaging procedures during the treatment protocol.
  • the condition of the liver, but also the amount of T cells or other cells of the immune system can be determined concomitantly in a conventional manner in order to obtain an overall view of the immunological constitution of the patient and in particular the constitution of metabolically important organs, in particular the
  • the clinical condition of the patient can be observed for the desired effect, in particular the antitumoral effect. Since tumor diseases can be associated with further, for example bacterial or fungicidal infections, it is also possible to additionally track the course of these accompanying infections clinically.
  • the patient may be treated with agents of the invention or other known drugs that may be expected to improve overall constitution.
  • agents of the invention or other known drugs that may be expected to improve overall constitution.
  • injections for example intramuscularly or subcutaneously or into the blood vessels, are a further preferred route for the therapeutic administration of the compounds according to the invention.
  • the delivery via catheters or surgical tubes can be used.
  • an optimal ratio of the compounds according to the invention to one another and / or with other therapeutic or activity-increasing agents such as transport inhibitors, metabolic inhibitors, inhibitors of renal excretion or glucuronidation, such as sample levan, acetaminophen, aspirin, lorazepan, cimetidine, ranitidine, colifibrate, Indomethacin, ketoprofen, naproxen, etc.
  • An optimal ratio is defined as the ratio at which the subject compound (s) to another therapeutic agent or agents are such that the overall therapeutic effect is greater than the sum of the effects of the individual therapeutic agents. The optimum ratio is usually found when the agents are present in a ratio of 10: 1 to 1:10, 20: 1 to 1: 20, 100: 1 to 1: 100 and 500: 1 to 1: 500.
  • the compounds of the invention may be used in combination with other known antitumoral agents.
  • the compounds of the invention may be administered by any conventional means, especially other drugs, available for use in the context of, in particular, tumor drugs, either as individual drugs or in combination of drugs. They can be administered alone or in combination with these.
  • the compounds of the invention are administered with the other known pharmaceutical agents in the ratio of about 0.005 to 1. It is preferred to administer the compounds according to the invention with in particular tumor-inhibiting agents in a ratio of 0.05 to about 0.5 parts to about 1 part of the known agents. These may also be antibacterial or other agents.
  • the pharmaceutical composition may be in bulk or as an aqueous solution along with other materials such as preservatives, buffering agents, agents intended to adjust the osmolarity of the solution, etc.
  • a Pradrug contains its active ingredient in the form of a non-active precursor metabolite.
  • Carrier prodrug systems contain the active ingredient as such, linked to a masking group that can be cleaved off by the simplest controllable mechanism.
  • the function according to the invention of masking groups in the compounds according to the invention is the neutralization of the charge for improved cell uptake.
  • the compounds according to the invention are used with a masking group, this may additionally influence other pharmacological parameters, such as oral bioavailability, tissue distribution, pharmacokinetics and stability towards non-specific phosphatases.
  • the delayed release of the active ingredient may also bring about a depot effect.
  • a modified metabolization may occur, resulting in higher drug efficiency or organic specificity.
  • the masking group or linker group that binds the masking group to the drug is selected so that the prodrug has sufficient hydrophilicity to be dissolved in the blood serum, has sufficient chemical and enzymatic stability, to reach the site of action to reach and has such a hydrophilicity that it is suitable for a drffusionskontroll mandat membrane transport.
  • the compound without a mask or a linker and a mask can also be regarded as a prodrug, which first has to be provided by enzymatic and biochemical processes from the absorbed compound in the cell.
  • the pharmaceutical agent according to the invention is used in total amounts of 0.05 to 500 mg per kg, preferably from 5 to 100 mg per kg body weight, per 24 hours.
  • the preparation is administered orally, subcutaneously, intravenously, intramuscularly, intraperitoneally and / or topically.
  • the agents according to the invention, the pharmaceutical agents according to the invention and the kit according to the invention are used for the secondary prophylaxis of tumors.
  • the invention also relates to the use of the compounds of the invention or the molecules of the invention according to the general formulas 1 to 16 as a lead structure for the development of polymerase inhibitors.
  • the advantageous embodiments of the invention have at least one or more of the advantages mentioned.
  • Substance 10 is characterized by a strong cytotoxic effect on non-contact-inhibited (FIG. 1) and contact-inhibited (Table 1) tumor cells (SCC-25 cells). This is stronger than with primary keratinocytes (Kc). This results in selective damage to the skin tumor.
  • BuP-OH is the particularly strong antiprolferative effect on tumor cells (SCC-25), which exceeds that of HM-1 and HM-1 oxime (FIG. 2).
  • SCC-25 tumor cells
  • HM-1 and HM-1 oxime FIG. 2
  • For tumor cells, there is a certain selectivity Effect is stronger than on primary keratinocytes and Ha-CaT cells (FIG. 3, Tab. 1).
  • Keratinocyte cell line HaCaT in no way.
  • parallel molecular modeling calculations yielded particularly high affinity for the binding site.
  • substances which can also be cytotoxic to dermal fibroblasts can be modified by means of the preferred carrier systems in such a way that the toxic effect is reduced if the carrier systems used are those which aim at an accumulation of the drug in the epidermis ,
  • solid lipid nanoparticles 150-170 nm
  • dendritic core-shell nanotransporters (20-30 nm) increase epidermal penetration 3-6-fold resp. 8-13-fold.
  • the LogP values of the guanosine analogues (group 6) and guanosine phosphonate analogues (group 8) are of the same order of magnitude as those of glucocorfiocides (prednisolone, prednicar-bat), in particular the prednicarbate, which can be integrated in the long term in a stable manner (see Tab 3, [C. Santos Maia, W. Mehnert, M. Schaller, HC Körting, A. Gysier, A. Haberland, M. Schafer-Körting, Drug targeting by solid lipid nanoparticles fordermal use. "J Drug Targeting 10 (2002) 489 ⁇ 951]) and therefore open surprisingly good conditions for the preparation of lipid nanoparticles high stability. This makes them particularly suitable for drug production.
  • FIG. 1 Effect of substance 10 (HM-1) and BuPOH on the tumor cell line SCC-25 and primary keratinocytes isolated from prepuce.
  • the effect of HM-1 on SCC-25 cells is stronger than in the two comparative substances 5-fluorouracil and aphidicolin.
  • FIG. 2 Viability (MTT test) after 48-hour exposure of SCC-25 cells to BuP-OH ( ⁇ ), HM-1 (O) and HM-1 oxime ( ⁇ ).
  • Fig. 3 Viability (MTT test) of HaCaT cells ( ⁇ ), keratinocytes (•) and SCC-25 cells (A) after 48 hours exposure to BuP-OH.
  • FIG. 4 Penetration enhancement of the model substance Nile Red on loading of solid lipid nanoparticles (SLN) or dendritic core-shell nanotransporters compared with a cream; Application time h.
  • the preparation or synthesis of the antitumor agents according to the invention for topical application is shown in FIG.
  • the synthesized products 6, 9, 12, 15, 23, 28, 33, 37, 42, 46 and / or 51 are, for example, particularly well applicable topically as antitumor agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs de polymérase, notamment des inhibiteurs de polymérase alpha, et leur utilisation lors de dysfonctionnements cellulaires, notamment de maladies tumorales, de préférence pour des kératoses actiniques, des basaliomes et/ou des carcinomes spinocellulaires.
EP08758070A 2007-05-11 2008-05-13 Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs Withdrawn EP2152273A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08758070A EP2152273A2 (fr) 2007-05-11 2008-05-13 Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP07090098A EP1990054A1 (fr) 2007-05-11 2007-05-11 Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs
EP07090106 2007-05-30
EP07075656 2007-07-30
DE102007041968 2007-08-31
EP07075752 2007-09-03
DE102007044849 2007-09-13
EP07075853 2007-09-28
DE102008003477 2008-01-04
EP08758070A EP2152273A2 (fr) 2007-05-11 2008-05-13 Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs
PCT/DE2008/000818 WO2008138327A2 (fr) 2007-05-11 2008-05-13 Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs

Publications (1)

Publication Number Publication Date
EP2152273A2 true EP2152273A2 (fr) 2010-02-17

Family

ID=40002671

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08758070A Withdrawn EP2152273A2 (fr) 2007-05-11 2008-05-13 Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs

Country Status (9)

Country Link
US (1) US20110182973A1 (fr)
EP (1) EP2152273A2 (fr)
JP (1) JP2010526839A (fr)
CN (1) CN101808644A (fr)
AU (1) AU2008250809B2 (fr)
BR (1) BRPI0810682A2 (fr)
CA (1) CA2687007A1 (fr)
MX (1) MX2009011388A (fr)
WO (1) WO2008138327A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6122960B2 (ja) * 2012-10-08 2017-04-26 ダウ グローバル テクノロジーズ エルエルシー 難燃性ポリウレタンフォーム用の有機リン化合物
CN105884628B (zh) * 2016-06-06 2018-06-29 上海工程技术大学 2,4-二叔丁基-5-氨基酚的制备方法
WO2018057366A1 (fr) * 2016-09-20 2018-03-29 Lanxess Solutions Us Inc. Antioxydants à base de 3-hydroxydiphénylamines alkylées
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663446A (en) * 1983-06-27 1987-05-05 Trustees Of The Univ. Of Massachusetts N2 (phenyl substituted) deoxy guanosine containing compounds
US5646155A (en) * 1994-05-12 1997-07-08 University Of Massachusetts Medical Center Drugs to prevent recurrent herpes virus infections
RU2111970C1 (ru) * 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
JP5149168B2 (ja) * 2005-06-07 2013-02-20 エール ユニヴァーシティ Ｌｆｍａｕおよびｌｄｔを用いる癌および他の症状または病状の処置方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008138327A2 *

Also Published As

Publication number Publication date
CA2687007A1 (fr) 2008-11-20
AU2008250809A1 (en) 2008-11-20
JP2010526839A (ja) 2010-08-05
BRPI0810682A2 (pt) 2016-11-16
WO2008138327A2 (fr) 2008-11-20
MX2009011388A (es) 2010-03-30
AU2008250809A2 (en) 2010-04-22
WO2008138327A3 (fr) 2009-05-28
WO2008138327A9 (fr) 2009-12-30
AU2008250809B2 (en) 2010-09-30
CN101808644A (zh) 2010-08-18
US20110182973A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
DE69631134T2 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
DE69634733T2 (de) Benzamidoxime prodrugs und verwendung zur behandlung von pneumonie
DE3611194A1 (de) Cancerostatisches mittel
DE69634074T2 (de) Thiole zur Förderung des Wachstums von Hömatopoietischen Vorläuferzellen
DE60220666T2 (de) Steigerung der wirksamkeit von wirkstoffen durch micellare zubereitung mit retinolderivaten
DE102013107025A1 (de) Methoden und zusammensetzungen zur behanldung von diabetis
EP2152273A2 (fr) Inhibiteurs de polymérase et leur utilisation pour le traitement de tumeurs
EP1850830B1 (fr) Suppositoire destine a lier des composes oxygene reactifs dans le corps d'un homme ou d'un animal
DE60035120T2 (de) Behandlung von krebserkrankungen durch aplidin
EP0205775A2 (fr) Médicament contenant des constituants de Caesalpinia
DE60018704T2 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE2900203A1 (de) Krebshemmendes und krebsmetastasen verhinderndes arzneimittel
WO2005058816A1 (fr) Derives de proline comme principes actifs pharmaceutiques dans la therapie des tumeurs
EP0334243B1 (fr) Médicament contenant des amines d'acridine pour le traitement iontophorétiques des carcinomes
DE102005053011A1 (de) Tetraorganosilicium-Verbindungen, ihre Verwendung, ihre Verwendung zur Herstellung von Vesikeln, aus ihnen hergestellte Vesikel (Siosomen) und deren Verwendung als Wirkstoffe, Träger von Wirkstoffen und Verfahren zur Herstellung von Vesikeln
EP1524273B1 (fr) Procédure pour la preparation des sels et derivées de trans- et cis-diammoniumdichlorodihydroxyplatine et leur usage pour la preparation des agents pharmaceutique
DE60206169T2 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
EP1685134B1 (fr) Nouveaux derives de chelidonine, leur procede de production et leur utilisation pour produire des principes actifs pharmaceutiques
EP1001756B1 (fr) Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
CN113116884A (zh) 川陈皮素在制备预防或治疗与施用化疗药物相关的皮肤组织疾病或病症的药物上的应用
WO2005056005A1 (fr) Agents de combinaison chp-gemcitabine et utilisation en tant qu'agents antitumoraux
WO2005039605A1 (fr) Composition pharmaceutique contenant de l'oxoplatine, ses sels et derives
DE2518509C3 (de) Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin
EP1640012A1 (fr) Agents pharmaceutiques comprenant des constituants du sang 10 kDa et l'utilisation dans la prophylaxe et dans le traitement des troubles du système immunitaire
EP2130832A1 (fr) Complexes organiques de cuivre, leur utilisation en tant que produit anti-tumeur et pour la protection des tissus sains contre le rayonnement ionisant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20100520

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201